Answers are grounded in this paper and cite their sources.
Finds early immune recovery during adjuvant anti–PD-1 predicts early recurrence in melanoma, suggesting proactive monitoring benefits.
e21545 Background: Early identification of patients at risk of recurrence during adjuvant anti–PD-1 remains an unmet need. We tested whether a longitudinal Time-in-Range (TIR) metric capturing time spent in an “immune-recovered” state during weeks 0–12 predicts early post-landmark recurrence. Methods: Consecutive AJCC 8th stage II–III melanoma patients receiving adjuvant nivolumab or pembrolizumab (n = 74) underwent routine CBC monitoring approximately every 2 weeks during weeks 0–12 (median 7 measurements/patient). The immune-recovered range was prespecified as NLR < 3 AND ALC ≥1.0×10⁹/L. TIR(0–12) was calculated using interval-based time-weighting between consecutive measurements. Secondary prespecified dynamics included ALC slope (0–12) and time-adjusted RMSSD of log(NLR). To mitigate guarantee-time bias, we applied a 12-week landmark: patients recurring before week 12 were excluded, and the primary endpoint was early recurrence from week 12 to month 12; secondary endpoint was 12-month RFS. Parsimonious models adjusted for stage and ulceration; sensitivity analyses tested alternative thresholds (NLR < 4; ALC ≥0.8×10⁹/L) and exclusion of intercurrent infection/inflammation in weeks 0–12. Results: Median age was 61 years (IQR 53–68.8); stage III 52.7%; ulceration 45.9%; nivolumab 55.4%. Intercurrent infection/inflammation in weeks 0–12 occurred in 17.6%. Overall 12-month recurrence was 24/74 (32.4%). Early recurrence < 12 months occurred in 13/74 (17.6%). One patient recurred before week 12; 73 comprised the landmark cohort, with 12/73 (16.4%) early post-landmark recurrences. Median TIR was 0.0% in early post-landmark recurrences versus 18.5% in non-recurrences. In adjusted logistic regression, higher TIR was associated with lower odds of early post-landmark recurrence (OR 0.74 per +10% TIR, 95% CI 0.57–0.95). Categorized for interpretability, the highest TIR tertile had lower early recurrence than the other tertiles combined (4.2% vs 24.0%; adjusted OR 0.06, 95% CI 0.007–0.59). Discrimination remained favorable after bootstrap optimism correction (AUC 0.83). Secondary dynamics were directionally consistent (lower ALC slope, higher NLR volatility among early recurrences). Twelve-month RFS was 78.3% overall and 95.8% in the highest TIR tertile; associations were consistent when excluding intercurrent infection/inflammation. Conclusions: A simple longitudinal metric—time spent in an immune-recovered range during the first 12 weeks of adjuvant anti–PD-1—was independently associated with early post-landmark recurrence, suggesting an actionable early window for risk-adapted surveillance. External validation is warranted.
No takes yet. Share an insight, caveat, or question.
Raimondi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: